These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34450472)

  • 21. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
    Lehmann K; Kuhn S; Schulte B; Verthein U
    Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
    Arunogiri S; Lintzeris N
    J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting depot buprenorphine in people who are homeless: Views and experiences.
    Matheson C; Foster R; Schofield J; Browne T
    J Subst Abuse Treat; 2022 Aug; 139():108781. PubMed ID: 35450752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.
    Zahra E; Chen R; Nielsen S; Tran AD; Santo T; Degenhardt L; Farrell M; Byrne J; Ali R; Larance B
    Drug Alcohol Rev; 2022 May; 41(4):841-850. PubMed ID: 35130368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New slow-release buprenorphine formulations for optimization of opioid substitution].
    Soyka M; Pogarell O
    Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
    Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
    Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.
    Bharat C; Chidwick K; Gisev N; Farrell M; Ali R; Degenhardt L
    Int J Drug Policy; 2024 Jan; 123():104255. PubMed ID: 38029481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study.
    Trevitt BT; Hayes V; Deacon R; Mills L; Demirkol A; Lintzeris N
    BMC Public Health; 2024 Feb; 24(1):349. PubMed ID: 38308232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
    Lintzeris N; Hayes V; Dunlop AJ
    Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.